These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29037611)

  • 1. Improvement in the Management of Dyslipidemia in a Clinical Practice Population at Very High Cardiovascular Risk. The COLIPAR Project.
    Cosín-Sales J; Gisbert-Criado R; Maceira AM; Buendía F; Gómez Ribelles R; Ruvira J
    Rev Esp Cardiol (Engl Ed); 2018 Nov; 71(11):979-980. PubMed ID: 29037611
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing cardiovascular risk and managing dyslipidemia in women.
    Appel SJ; Floyd NA; Jones EJ
    Nurs Womens Health; 2007 Dec; 11(6):586-99. PubMed ID: 18088296
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of dyslipidemia: we don't know all we think we know.
    LeLorier J
    Can J Cardiol; 2006 Jul; 22(9):737-8. PubMed ID: 16913059
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating dyslipidemia: something more than giving statins.
    Masana L
    Clin Investig Arterioscler; 2019; 31(3):119-120. PubMed ID: 31014747
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy and clinical trials.
    Cusi K
    Curr Opin Lipidol; 2015 Oct; 26(5):472-4. PubMed ID: 26339771
    [No Abstract]   [Full Text] [Related]  

  • 7. [To improve cardiovascular health: we are forced for not loosing impulse].
    Millán Núñez-Cortés J; Mantilla Morató T; Lobos Bejarano JM; Pedro-Botet Montoya J
    Clin Investig Arterioscler; 2016; 28(1):43-6. PubMed ID: 26589871
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid management: maximising reduction of cardiac risk.
    Webb J; Gonna H; Ray KK
    Clin Med (Lond); 2013 Dec; 13(6):618-20. PubMed ID: 24298114
    [No Abstract]   [Full Text] [Related]  

  • 11. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.
    Genest J; McPherson R; Frohlich J; Anderson T; Campbell N; Carpentier A; Couture P; Dufour R; Fodor G; Francis GA; Grover S; Gupta M; Hegele RA; Lau DC; Leiter L; Lewis GF; Lonn E; Mancini GB; Ng D; Pearson GJ; Sniderman A; Stone JA; Ur E
    Can J Cardiol; 2009 Oct; 25(10):567-79. PubMed ID: 19812802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dyslipidemia in patients with chronic kidney disease.
    Marino A; Tannock LR
    Postgrad Med; 2013 Jul; 125(4):28-37. PubMed ID: 23842535
    [No Abstract]   [Full Text] [Related]  

  • 13. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 14. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrates consistently lower risk of cardiovascular events across high-risk groups.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):174. PubMed ID: 20532463
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reasons for a combination].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
    [No Abstract]   [Full Text] [Related]  

  • 17. [Part I. Fibrates in primary and secondary prevention].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia in menopause: mechanisms and management.
    Schnatz PF; Schnatz JD
    Obstet Gynecol Surv; 2006 Sep; 61(9):608-13. PubMed ID: 16919179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis.
    Wierzbicki AS; Morrell J; Hemsley D; McMahon Z; Crook MA; Wray R
    Curr Med Res Opin; 2010 Sep; 26(9):2141-6. PubMed ID: 20662558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.